Statistically significant linear decrease in use of antidepressants, antipsychotics, psychostimulants and nootropic drugs, anxiolytics, sedatives and hypnotics during the observed time period. by Jelena Filimonovic (22305307)

Estimated mean values for light interception. by Torsten Schober (20485754)

“…An increase in PD led to a linear decrease in inflorescence yield per plant (<i>p</i> = 0.02), whereas a positive linear relationship was found for inflorescence yield (<i>p</i> = 0.0001) and CBD yield (<i>p</i> = 0.0002) per m². …”

Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “... by Mobina Faqani (22783963)

Statistically significant linear increase in use of antidementia medications and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

Sample size (n) and mean (± SD) of ẟ¹³C, ẟ¹⁵N, ẟ¹³C_corr, and trophic position (TP) values, and minimum and maximum ẟ¹³C and ẟ... by Danny Rejas (583637)

Subjects:

Linear regression equation and concentration range of each SCFAs standard. by Shudan Liu (7049483)

Subjects:

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…Results are presented as mean ± SD. Ceramide: CER, Evogliptin: EVO. *(P < 0.05) significant vs. control group; ^$(P < 0.05) significant vs. …”

Join-point regression analysis of the statistically significant linear increase in use of antidepressants during the observed time period. by Jelena Filimonovic (22305307)

Boxplot mean cfPWV comparisons. by Johannes Nairz (18010746)

Subjects:

Linear relationship between sleep duration and cardiovascular disease (CVD) risk in type 2 diabetes patients. by Zhi Jin (3742471)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

Subjects:

Impact on different areas of health. by Margherita Molaro (17803989)

Join-point regression analysis of the statistically significant linear increase in use of antidementia and antipsychotics during the observed time period. by Jelena Filimonovic (22305307)

Marginal means – Pooled across scenarios. by Mehdi Mourali (10170245)

“…A randomized conjoint experiment and a follow-up choice experiment revealed that support for the EIAs decreased sharply as their accuracy gap grew, although impact parity was prioritized more when ETAs produced large outcome discrepancies. …”